NASDAQ · DRTSW
Healthcare · Biotechnology
$3.92
Down-$0.36 (-9.18%)
Updated Oct 9, 2026, 12:28 AM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · DRTSW
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 7, 2026
DRTSW closed at $3.92 after 20 trading sessions, down 2.00% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 7, 2026 | $3.81 | $4.05 | $3.60 | $3.92 | 38.93K |
| Oct 6, 2026 | $3.95 | $3.95 | $3.95 | $3.95 | 675 |
| Oct 5, 2026 | $4.19 | $4.26 | $4.19 | $4.26 | 13.58K |
| Oct 2, 2026 | $4.05 | $4.07 | $4.05 | $4.05 | 1.29K |
| Oct 1, 2026 | $4.03 | $4.12 | $3.88 | $4.02 | 16.31K |
| Sep 30, 2026 | $4.18 | $4.30 | $4.00 | $4.095 | 14.01K |
| Sep 29, 2026 | $4.04 | $4.30 | $3.98 | $4.18 | 15.39K |
| Sep 28, 2026 | $3.92 | $4.20 | $3.91 | $4.10 | 16.89K |
| Sep 25, 2026 | $4.00 | $4.00 | $3.90 | $3.92 | 1.58K |
| Sep 24, 2026 | $4.00 | $4.00 | $3.81 | $3.97 | 14.63K |
| Sep 23, 2026 | $4.15 | $4.275 | $3.79 | $4.00 | 51.12K |
| Sep 22, 2026 | $4.30 | $4.42 | $4.14 | $4.14 | 16.19K |
| Sep 21, 2026 | $4.45 | $4.45 | $4.10 | $4.37 | 46.91K |
| Sep 18, 2026 | $4.31 | $4.32 | $4.15 | $4.20 | 20.22K |
| Sep 17, 2026 | $4.09 | $4.62 | $4.00 | $4.37 | 210.59K |
| Sep 16, 2026 | $4.12 | $4.165 | $3.85 | $4.16 | 123.48K |
| Sep 15, 2026 | $3.72 | $4.10 | $3.56 | $4.04 | 154.95K |
| Sep 14, 2026 | $3.74 | $4.02 | $3.7201 | $3.7401 | 23.21K |
| Sep 11, 2026 | $4.07 | $4.07 | $3.70 | $3.8399 | 17.24K |
| Sep 10, 2026 | $3.81 | $4.19 | $3.67 | $4.00 | 45.8K |
The latest Smart Investors Daily articles mentioning DRTSW.
Company
Market Activity
Research & News
DRTSW research
Company profile and research snapshot.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
SeekingAlpha · Sep 11, 2026
Oramed Pharmaceuticals holds as it shifts to strategic investments; strong returns from Alpha Tau, Lifeward & Scilex, but risks loom. Click for an ORMP update.
Yahoo · Aug 31, 2026
- IMPACT, a multicenter pilot study of Alpha DaRT® for newly diagnosed unresectable pancreatic cancer, expanded enrollment three times over the course of the study, from an original enrollment of 12 patients to a total of 48 treated patients, driven by overwhelming demand from patients and clinicians - - Alpha DaRT is delivered as a one-time add-on alongside standard first-line chemotherapy, an approach supported by the favorable safety profile observed in the earlier Israeli and Canadian studie
Yahoo · Aug 28, 2026
By M. Marin NASDAQ: ORMP READ THE FULL ORMP RESEARCH REPORT Gains on investment portfolio + service agreement income contributed to 2Q26 EPS of $2.76 Oramed Pharmaceuticals (NASDAQ: ORMP) leverages its strong balance sheet, with $15.2 million of cash and equivalents and $50.6 million of cash and equivalents plus short-term investments, to allocate capital to investments in the biomedical and
Yahoo · Jul 7, 2026
AMPX, DRTS and BELFB have been added to the Zacks Rank #5 (Strong Sell) List on July 7, 2026.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning DRTSW.
No results
No recent SID articles mention DRTSW.
